John Vederas, BSc, PhD, FRSC, FRS
John Vederas is a Distinguished Professor in the Department of Chemistry at the University of Alberta. His group does research in medicinal chemistry and on natural product biosynthesis. Work on development of antiviral agents has included blocking replication of SARS-CoV-1 and more recently SARS-CoV-2, with inhibitors of the viral protease enzymes that generate building blocks for these infectious agents.
Personal Website: https://www.chem.ualberta.ca/~vederas/index.html
Publications
- Structural Insights into the nirmatrelvir-Resistant SARS-CoV-2 Mpro L50F/E166A/L167F Triple Mutant-Inhibitor-Complex Reveal Strategies for Next Generation Coronaviral Inhibitor Design
- A Structural Comparison of Oral SARS-CoV-2 Drug Candidate Ibuzatrelvir Complexed with the Main Protease (Mpro) of SARS-CoV-2 and MERS-CoV
- Discovery, Characterization, and Structure of a Cofactor-Independent Histidine Racemase from the Oral Pathogen Fusobacterium Nucleatum
- Assessment of Optimized FRET Substrates as Universal Corona- and Picornavirus Main protease Substrates for Screening Assays
- The Effect of Deuteration and Homologation of the Lactam Ring of Nirmatrelvir on Its Biochemical Properties and Oxidative Metabolism
- Deuteration for Metabolic Stabilization of SARS-CoV-2 Inhibitors GC373 and Nirmatrelvir